Osteoarthritis Clinical Trials

Find Osteoarthritis Clinical Trials Near You

The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy. The goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and/or knee osteoarthritis. Participants will: * Take either CBD, THC, or a placebo capsule daily for 8 weeks * Complete follow-ups remotely, with no in-person clinic visits required * Maintain a diary tracking their study drug usage and any additional pain medications

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:

• Age 40-80 years

• Diagnosed with hip and/or knee osteoarthritis as per the American College of Rheumatology criteria

• Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60

• Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks

• Able to self-report, understand and read English or French

Locations
Other Locations
Canada
McGill University Health Centre/Montreal General Hospital
NOT_YET_RECRUITING
Montreal
University Health Network
RECRUITING
Toronto
Women's College Hospital
RECRUITING
Toronto
Contact Information
Primary
Sonal Thaker
sonalben.thaker@uhn.ca
1-416-340-4800
Backup
Deep Grewal
Deep.Grewal@uhn.ca
1-416-340-4800
Time Frame
Start Date: 2026-01-29
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 100
Treatments
Experimental: CBD (Cannabidiol)
Each capsule contains a concentration of 50 mg of Cannabidiol (CBD). Participants will receive CBD for a total duration of 8 weeks.
Experimental: THC (∆9-tetrahydrocannabinol)
Each capsule contains a concentration of 3 mg of ∆9-tetrahydrocannabinol (THC). Participants will receive THC capsules for a total duration of 8 weeks.
Placebo_comparator: Placebo
Participants will receive matching placebo capsules for a total duration of 8 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: Canadian Institutes of Health Research (CIHR)
Leads: University Health Network, Toronto

This content was sourced from clinicaltrials.gov

Similar Clinical Trials